Loading…

Survey Result for E-labeling Initiatives in Asia

Under the COVID-19 pandemic, various electronic labeling initiatives have accelerated worldwide in the healthcare and pharmaceutical fields as part of a wider digital transformation [ 1 , 2 ]. Although there is no universal definition of electronic labeling (e-labeling) globally, it is widely unders...

Full description

Saved in:
Bibliographic Details
Published in:Therapeutic innovation & regulatory science 2023-03, Vol.57 (2), p.251-260
Main Authors: Matsui, Rie, Yamaguchi, Koji, Lee, Jadz Jevz Venzon, Ting, Ivy, Khairilisani, Destita, Chang, Jenny, Seo, Jeong-Min, Park, Ina, Chee, Alice Seat Mee, Quizon, Paul Marvin, Harnpramukkul, Usanee, Sem, Ellen, Nguyen, Thuy, Padhye, Anagha, Mo, Runyi
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c355t-8a0ee3b9881c105e29ba513523c18329811b96da8e326fe7a255e0ffe5ba2c63
container_end_page 260
container_issue 2
container_start_page 251
container_title Therapeutic innovation & regulatory science
container_volume 57
creator Matsui, Rie
Yamaguchi, Koji
Lee, Jadz Jevz Venzon
Ting, Ivy
Khairilisani, Destita
Chang, Jenny
Seo, Jeong-Min
Park, Ina
Chee, Alice Seat Mee
Quizon, Paul Marvin
Harnpramukkul, Usanee
Sem, Ellen
Nguyen, Thuy
Padhye, Anagha
Mo, Runyi
description Under the COVID-19 pandemic, various electronic labeling initiatives have accelerated worldwide in the healthcare and pharmaceutical fields as part of a wider digital transformation [ 1 , 2 ]. Although there is no universal definition of electronic labeling (e-labeling) globally, it is widely understood that e-labeling refers to the product information that is distributed via electronic means. There are 5 factors to be considered in e-labeling, and these are discussed in this publication. APAC is an industry-driven initiative with 13 R&D-based pharmaceutical associations joining from 11 markets in Asia. e-labeling was discussed as a new topic starting in 2020, and a 22-question survey was conducted in November 2021 to understand the current e-labeling status. The survey results showed that e-labeling initiatives were at different levels of maturity in the Asian region, although most markets have started to discuss e-labeling initiatives. Various challenges exist around e-labeling initiatives due to a variety of different approaches being taken in the region. It would be advisable to develop regional guidance on how to proceed with e-labeling initiatives in the Asian region to have a consistent and efficient approach. The close collaboration between agencies, Health Care Professionals (HCPs), patients, and industry associations is important to move e-labeling initiatives forward in Asia.
doi_str_mv 10.1007/s43441-022-00462-5
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9549856</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2774230706</sourcerecordid><originalsourceid>FETCH-LOGICAL-c355t-8a0ee3b9881c105e29ba513523c18329811b96da8e326fe7a255e0ffe5ba2c63</originalsourceid><addsrcrecordid>eNp9kU1LxDAQhoMorqz-AQ9S8OKlOpkkbXoRRNYPEAT1HtLudI10W03ahf33Zl3Xr4NzycC882ReXsYOOZxygPwsSCElTwExBZAZpmqL7SHPdCo1yO1NnxcwYgchvECsQqsc9S4biQy5AtR7DB4Hv6Bl8kBhaPqk7nwySRtbUuPaWXLbut7Z3i0oJK5NLoKz-2yntk2gg893zJ6uJk-XN-nd_fXt5cVdWgml-lRbIBJloTWvOCjCorSKC4Wi4lpgoTkvi2xqNQnMasotKkVQ16RKi1Umxux8jX0dyjlNK2p7bxvz6t3c-qXprDO_J617NrNuYQolo80V4OQT4Lu3gUJv5i5U1DS2pW4IBnMUUisVLxqz4z_Sl27wbXQXVblEATmsgLhWVb4LwVP9dQwHs4rErCMxMRLzEYlRcenop42vlU0AUSDWghBH7Yz899__YN8B_iyVKw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2774230706</pqid></control><display><type>article</type><title>Survey Result for E-labeling Initiatives in Asia</title><source>Springer Nature</source><creator>Matsui, Rie ; Yamaguchi, Koji ; Lee, Jadz Jevz Venzon ; Ting, Ivy ; Khairilisani, Destita ; Chang, Jenny ; Seo, Jeong-Min ; Park, Ina ; Chee, Alice Seat Mee ; Quizon, Paul Marvin ; Harnpramukkul, Usanee ; Sem, Ellen ; Nguyen, Thuy ; Padhye, Anagha ; Mo, Runyi</creator><creatorcontrib>Matsui, Rie ; Yamaguchi, Koji ; Lee, Jadz Jevz Venzon ; Ting, Ivy ; Khairilisani, Destita ; Chang, Jenny ; Seo, Jeong-Min ; Park, Ina ; Chee, Alice Seat Mee ; Quizon, Paul Marvin ; Harnpramukkul, Usanee ; Sem, Ellen ; Nguyen, Thuy ; Padhye, Anagha ; Mo, Runyi</creatorcontrib><description>Under the COVID-19 pandemic, various electronic labeling initiatives have accelerated worldwide in the healthcare and pharmaceutical fields as part of a wider digital transformation [ 1 , 2 ]. Although there is no universal definition of electronic labeling (e-labeling) globally, it is widely understood that e-labeling refers to the product information that is distributed via electronic means. There are 5 factors to be considered in e-labeling, and these are discussed in this publication. APAC is an industry-driven initiative with 13 R&amp;D-based pharmaceutical associations joining from 11 markets in Asia. e-labeling was discussed as a new topic starting in 2020, and a 22-question survey was conducted in November 2021 to understand the current e-labeling status. The survey results showed that e-labeling initiatives were at different levels of maturity in the Asian region, although most markets have started to discuss e-labeling initiatives. Various challenges exist around e-labeling initiatives due to a variety of different approaches being taken in the region. It would be advisable to develop regional guidance on how to proceed with e-labeling initiatives in the Asian region to have a consistent and efficient approach. The close collaboration between agencies, Health Care Professionals (HCPs), patients, and industry associations is important to move e-labeling initiatives forward in Asia.</description><identifier>ISSN: 2168-4790</identifier><identifier>EISSN: 2168-4804</identifier><identifier>DOI: 10.1007/s43441-022-00462-5</identifier><identifier>PMID: 36215028</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Asia ; COVID-19 ; Digital transformation ; Drug Safety and Pharmacovigilance ; Health care ; Health Personnel ; Humans ; Labeling ; Medical electronics ; Medicine ; Original Research ; Pandemics ; Pharmaceutical Preparations ; Pharmaceuticals ; Pharmacotherapy ; Pharmacy ; Product information ; Regional development ; Surveys</subject><ispartof>Therapeutic innovation &amp; regulatory science, 2023-03, Vol.57 (2), p.251-260</ispartof><rights>The Author(s) 2022</rights><rights>2022. The Author(s).</rights><rights>The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c355t-8a0ee3b9881c105e29ba513523c18329811b96da8e326fe7a255e0ffe5ba2c63</cites><orcidid>0000-0001-7975-1947</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36215028$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Matsui, Rie</creatorcontrib><creatorcontrib>Yamaguchi, Koji</creatorcontrib><creatorcontrib>Lee, Jadz Jevz Venzon</creatorcontrib><creatorcontrib>Ting, Ivy</creatorcontrib><creatorcontrib>Khairilisani, Destita</creatorcontrib><creatorcontrib>Chang, Jenny</creatorcontrib><creatorcontrib>Seo, Jeong-Min</creatorcontrib><creatorcontrib>Park, Ina</creatorcontrib><creatorcontrib>Chee, Alice Seat Mee</creatorcontrib><creatorcontrib>Quizon, Paul Marvin</creatorcontrib><creatorcontrib>Harnpramukkul, Usanee</creatorcontrib><creatorcontrib>Sem, Ellen</creatorcontrib><creatorcontrib>Nguyen, Thuy</creatorcontrib><creatorcontrib>Padhye, Anagha</creatorcontrib><creatorcontrib>Mo, Runyi</creatorcontrib><title>Survey Result for E-labeling Initiatives in Asia</title><title>Therapeutic innovation &amp; regulatory science</title><addtitle>Ther Innov Regul Sci</addtitle><addtitle>Ther Innov Regul Sci</addtitle><description>Under the COVID-19 pandemic, various electronic labeling initiatives have accelerated worldwide in the healthcare and pharmaceutical fields as part of a wider digital transformation [ 1 , 2 ]. Although there is no universal definition of electronic labeling (e-labeling) globally, it is widely understood that e-labeling refers to the product information that is distributed via electronic means. There are 5 factors to be considered in e-labeling, and these are discussed in this publication. APAC is an industry-driven initiative with 13 R&amp;D-based pharmaceutical associations joining from 11 markets in Asia. e-labeling was discussed as a new topic starting in 2020, and a 22-question survey was conducted in November 2021 to understand the current e-labeling status. The survey results showed that e-labeling initiatives were at different levels of maturity in the Asian region, although most markets have started to discuss e-labeling initiatives. Various challenges exist around e-labeling initiatives due to a variety of different approaches being taken in the region. It would be advisable to develop regional guidance on how to proceed with e-labeling initiatives in the Asian region to have a consistent and efficient approach. The close collaboration between agencies, Health Care Professionals (HCPs), patients, and industry associations is important to move e-labeling initiatives forward in Asia.</description><subject>Asia</subject><subject>COVID-19</subject><subject>Digital transformation</subject><subject>Drug Safety and Pharmacovigilance</subject><subject>Health care</subject><subject>Health Personnel</subject><subject>Humans</subject><subject>Labeling</subject><subject>Medical electronics</subject><subject>Medicine</subject><subject>Original Research</subject><subject>Pandemics</subject><subject>Pharmaceutical Preparations</subject><subject>Pharmaceuticals</subject><subject>Pharmacotherapy</subject><subject>Pharmacy</subject><subject>Product information</subject><subject>Regional development</subject><subject>Surveys</subject><issn>2168-4790</issn><issn>2168-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kU1LxDAQhoMorqz-AQ9S8OKlOpkkbXoRRNYPEAT1HtLudI10W03ahf33Zl3Xr4NzycC882ReXsYOOZxygPwsSCElTwExBZAZpmqL7SHPdCo1yO1NnxcwYgchvECsQqsc9S4biQy5AtR7DB4Hv6Bl8kBhaPqk7nwySRtbUuPaWXLbut7Z3i0oJK5NLoKz-2yntk2gg893zJ6uJk-XN-nd_fXt5cVdWgml-lRbIBJloTWvOCjCorSKC4Wi4lpgoTkvi2xqNQnMasotKkVQ16RKi1Umxux8jX0dyjlNK2p7bxvz6t3c-qXprDO_J617NrNuYQolo80V4OQT4Lu3gUJv5i5U1DS2pW4IBnMUUisVLxqz4z_Sl27wbXQXVblEATmsgLhWVb4LwVP9dQwHs4rErCMxMRLzEYlRcenop42vlU0AUSDWghBH7Yz899__YN8B_iyVKw</recordid><startdate>20230301</startdate><enddate>20230301</enddate><creator>Matsui, Rie</creator><creator>Yamaguchi, Koji</creator><creator>Lee, Jadz Jevz Venzon</creator><creator>Ting, Ivy</creator><creator>Khairilisani, Destita</creator><creator>Chang, Jenny</creator><creator>Seo, Jeong-Min</creator><creator>Park, Ina</creator><creator>Chee, Alice Seat Mee</creator><creator>Quizon, Paul Marvin</creator><creator>Harnpramukkul, Usanee</creator><creator>Sem, Ellen</creator><creator>Nguyen, Thuy</creator><creator>Padhye, Anagha</creator><creator>Mo, Runyi</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U7</scope><scope>C1K</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-7975-1947</orcidid></search><sort><creationdate>20230301</creationdate><title>Survey Result for E-labeling Initiatives in Asia</title><author>Matsui, Rie ; Yamaguchi, Koji ; Lee, Jadz Jevz Venzon ; Ting, Ivy ; Khairilisani, Destita ; Chang, Jenny ; Seo, Jeong-Min ; Park, Ina ; Chee, Alice Seat Mee ; Quizon, Paul Marvin ; Harnpramukkul, Usanee ; Sem, Ellen ; Nguyen, Thuy ; Padhye, Anagha ; Mo, Runyi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c355t-8a0ee3b9881c105e29ba513523c18329811b96da8e326fe7a255e0ffe5ba2c63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Asia</topic><topic>COVID-19</topic><topic>Digital transformation</topic><topic>Drug Safety and Pharmacovigilance</topic><topic>Health care</topic><topic>Health Personnel</topic><topic>Humans</topic><topic>Labeling</topic><topic>Medical electronics</topic><topic>Medicine</topic><topic>Original Research</topic><topic>Pandemics</topic><topic>Pharmaceutical Preparations</topic><topic>Pharmaceuticals</topic><topic>Pharmacotherapy</topic><topic>Pharmacy</topic><topic>Product information</topic><topic>Regional development</topic><topic>Surveys</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Matsui, Rie</creatorcontrib><creatorcontrib>Yamaguchi, Koji</creatorcontrib><creatorcontrib>Lee, Jadz Jevz Venzon</creatorcontrib><creatorcontrib>Ting, Ivy</creatorcontrib><creatorcontrib>Khairilisani, Destita</creatorcontrib><creatorcontrib>Chang, Jenny</creatorcontrib><creatorcontrib>Seo, Jeong-Min</creatorcontrib><creatorcontrib>Park, Ina</creatorcontrib><creatorcontrib>Chee, Alice Seat Mee</creatorcontrib><creatorcontrib>Quizon, Paul Marvin</creatorcontrib><creatorcontrib>Harnpramukkul, Usanee</creatorcontrib><creatorcontrib>Sem, Ellen</creatorcontrib><creatorcontrib>Nguyen, Thuy</creatorcontrib><creatorcontrib>Padhye, Anagha</creatorcontrib><creatorcontrib>Mo, Runyi</creatorcontrib><collection>SpringerOpen</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Therapeutic innovation &amp; regulatory science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Matsui, Rie</au><au>Yamaguchi, Koji</au><au>Lee, Jadz Jevz Venzon</au><au>Ting, Ivy</au><au>Khairilisani, Destita</au><au>Chang, Jenny</au><au>Seo, Jeong-Min</au><au>Park, Ina</au><au>Chee, Alice Seat Mee</au><au>Quizon, Paul Marvin</au><au>Harnpramukkul, Usanee</au><au>Sem, Ellen</au><au>Nguyen, Thuy</au><au>Padhye, Anagha</au><au>Mo, Runyi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Survey Result for E-labeling Initiatives in Asia</atitle><jtitle>Therapeutic innovation &amp; regulatory science</jtitle><stitle>Ther Innov Regul Sci</stitle><addtitle>Ther Innov Regul Sci</addtitle><date>2023-03-01</date><risdate>2023</risdate><volume>57</volume><issue>2</issue><spage>251</spage><epage>260</epage><pages>251-260</pages><issn>2168-4790</issn><eissn>2168-4804</eissn><abstract>Under the COVID-19 pandemic, various electronic labeling initiatives have accelerated worldwide in the healthcare and pharmaceutical fields as part of a wider digital transformation [ 1 , 2 ]. Although there is no universal definition of electronic labeling (e-labeling) globally, it is widely understood that e-labeling refers to the product information that is distributed via electronic means. There are 5 factors to be considered in e-labeling, and these are discussed in this publication. APAC is an industry-driven initiative with 13 R&amp;D-based pharmaceutical associations joining from 11 markets in Asia. e-labeling was discussed as a new topic starting in 2020, and a 22-question survey was conducted in November 2021 to understand the current e-labeling status. The survey results showed that e-labeling initiatives were at different levels of maturity in the Asian region, although most markets have started to discuss e-labeling initiatives. Various challenges exist around e-labeling initiatives due to a variety of different approaches being taken in the region. It would be advisable to develop regional guidance on how to proceed with e-labeling initiatives in the Asian region to have a consistent and efficient approach. The close collaboration between agencies, Health Care Professionals (HCPs), patients, and industry associations is important to move e-labeling initiatives forward in Asia.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>36215028</pmid><doi>10.1007/s43441-022-00462-5</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0001-7975-1947</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2168-4790
ispartof Therapeutic innovation & regulatory science, 2023-03, Vol.57 (2), p.251-260
issn 2168-4790
2168-4804
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9549856
source Springer Nature
subjects Asia
COVID-19
Digital transformation
Drug Safety and Pharmacovigilance
Health care
Health Personnel
Humans
Labeling
Medical electronics
Medicine
Original Research
Pandemics
Pharmaceutical Preparations
Pharmaceuticals
Pharmacotherapy
Pharmacy
Product information
Regional development
Surveys
title Survey Result for E-labeling Initiatives in Asia
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T22%3A15%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Survey%20Result%20for%20E-labeling%20Initiatives%20in%20Asia&rft.jtitle=Therapeutic%20innovation%20&%20regulatory%20science&rft.au=Matsui,%20Rie&rft.date=2023-03-01&rft.volume=57&rft.issue=2&rft.spage=251&rft.epage=260&rft.pages=251-260&rft.issn=2168-4790&rft.eissn=2168-4804&rft_id=info:doi/10.1007/s43441-022-00462-5&rft_dat=%3Cproquest_pubme%3E2774230706%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c355t-8a0ee3b9881c105e29ba513523c18329811b96da8e326fe7a255e0ffe5ba2c63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2774230706&rft_id=info:pmid/36215028&rfr_iscdi=true